Overview
ARVN market data
Price History
ARVN price chart
Valuation & Profitability
- P/E (TTM)
- 63.10 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.14 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.79 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.32 – $14.51 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $586.8M · P/B 1.76 · P/S 1.85.
Company News
Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14Benzinga · Aug 10, 2026, 4:17 PM
Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21Benzinga · Aug 10, 2026, 3:14 PM
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11Benzinga · Aug 5, 2026, 1:44 PM
Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12Benzinga · Aug 5, 2026, 1:19 PM
BTIG Reiterates Buy on Arvinas, Maintains $18 Price TargetBenzinga · Aug 4, 2026, 5:45 PM
Transcript: Arvinas Q2 2026 Earnings Conference CallBenzinga · Aug 4, 2026, 1:10 PM
Arvinas shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 4, 2026, 12:50 PM
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M EstimateBenzinga · Aug 4, 2026, 11:06 AM
8-K filing — ARVINAS, INC. (ARVN)SEC EDGAR · Aug 4, 2026, 11:02 AM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga · Jun 16, 2026, 8:10 PM